Atossa Therapeutics, Inc. develops clinical-stage medicines for oncology and other areas of unmet medical need. Its recurring news centers on (Z)-endoxifen, the company's lead product candidate, including breast cancer research, mammographic breast density data, and expansion into rare disease indications such as Duchenne muscular dystrophy and McCune-Albright Syndrome.
Company updates also cover FDA orphan and rare pediatric disease designations, clinical and preclinical data presentations, peer-reviewed publications, intellectual property developments, leadership additions, financial results, and capital-allocation commentary tied to Atossa's development strategy.
Atossa Therapeutics (ATOS) executed a contingent value rights agreement giving shareholders contractual participation in potential priority review voucher proceeds. The board declared one contingent value right (CVR) per common share outstanding at the close of business on October 19, 2026. Shares issued afterward also carry one CVR until detachment or agreement expiration.
Holders are entitled collectively to 25% of net proceeds from sale or deemed monetization of the first qualifying FDA priority review voucher (PRV), capped at $50 million. The voucher must be awarded by December 31, 2036, unless the board extends the date. CVRs remain attached to shares unless the board detaches them. Atossa has rare pediatric disease designations for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome, but has submitted no marketing application for either indication and has received no PRV.
Atossa Therapeutics (ATOS) plans to issue one contingent value right (CVR) per common share, tied to a potential priority review voucher.
Holders would collectively receive 25% of net proceeds from Atossa’s first qualifying rare pediatric disease voucher, up to $50 million in total. The right would attach to shares held on a record date yet to be set and to shares issued afterward; it would transfer with the stock rather than trade separately. Atossa has FDA rare pediatric disease designations for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome. A voucher may be awarded if a qualifying marketing application is approved under the program’s requirements. No Atossa product candidate has been approved or voucher awarded. The rights would expire if no qualifying voucher is awarded by December 31, 2036, unless the board extends that date.
Atossa Therapeutics (ATOS) CEO Steven Quay will join an ARDD 2026 panel on clinical trials for diseases of aging on October 1.
The session is scheduled for 11:20 a.m. to 12:00 p.m. ET at Harvard University's David Rubenstein Treehouse in Boston. Panelists will discuss how evidence on aging and age-related diseases can inform clinical development and regulatory pathways.
Atossa Therapeutics (Nasdaq: ATOS) reported second quarter 2026 results and a corporate update centered on lead candidate (Z)-endoxifen. Total operating expenses were $8.7 million for Q2 2026 versus $9.0 million a year earlier, and $18.6 million for the first half versus $16.5 million in 2025.
R&D expense was $4.9 million in Q2, down 11% year-over-year, while G&A rose 7% to $3.8 million, driven by higher legal and IP-related fees. At June 30, 2026, Atossa reported $26.1 million in cash and cash equivalents and total stockholders’ equity of $26.8 million, compared with $41.3 million and $39.4 million at year-end 2025.
During the quarter, Atossa advanced (Z)-endoxifen across oncology and rare diseases, completed enrollment in the Phase 2 EVANGELINE breast cancer trial, highlighted new preclinical and mechanistic data at AACR and ASCO, and strengthened its balance sheet via a registered direct offering providing $4.5 million upfront and up to $12 million in additional warrant proceeds.
Atossa Therapeutics (NASDAQ: ATOS) announced a peer-reviewed preclinical study in npj Breast Cancer describing five novel (Z)-endoxifen-related compounds (AT416E, AT416Z, AT402E, AT402Z and AT300) evaluated alongside (Z)-endoxifen in multiple estrogen receptor-positive (ERα+) breast cancer models, including ESR1-mutant models.
The compounds showed anti-estrogenic and anti-cancer activity across assays of tumor growth, apoptosis, cell cycle, migration, invasion, and estrogen receptor-driven transcription. In certain models, combinations with the CDK4/6 inhibitor abemaciclib produced additive to synergistic activity comparable to or greater than abemaciclib plus (Z)-endoxifen. Investigators concluded select candidates warrant further in vivo safety and efficacy evaluation; Atossa emphasized the findings are preclinical and do not establish safety or efficacy in patients.
Atossa Therapeutics (NASDAQ: ATOS) reported preclinical findings on (Z)-endoxifen in McCune-Albright syndrome-associated peripheral precocious puberty (MAS-PPP) at the AACR Special Conference on Rare Cancers held July 18-20, 2026, in Vancouver, Canada.
The poster describes a dual mechanism of action in estrogen-driven pathology: blockade of estrogen receptor (ER)-mediated transcription downstream of autonomous estrogen production and suppression of PKC-β/AKT-related proliferative and cell-cycle signaling. Using weighted gene expression signatures in ER-positive MCF7 cells with integrated phosphoproteomic and RNA-seq datasets, (Z)-endoxifen was associated with marked downregulation of cell-cycle programs (including G2M Checkpoint and E2F Targets) and modulation of estrogen-response pathways. According to Atossa, these data support further evaluation of (Z)-endoxifen as a mechanism-driven candidate for MAS-PPP and potentially other estrogen-driven neoplasms.
Atossa Therapeutics (Nasdaq: ATOS) closed a registered direct offering of 1,363,637 common shares (or equivalents) plus Series A and short-term Series B warrants, raising about $4.5 million in gross proceeds.
The Series Warrants could add up to $12 million if fully exercised. Atossa plans to use net proceeds for clinical development, working capital and general corporate purposes.
Atossa Therapeutics (Nasdaq: ATOS) entered a securities purchase agreement for a registered direct offering of 1,363,638 common shares (or equivalents) plus Series A and short-term Series B warrants.
The deal is expected to raise about $4.5 million upfront, with up to $12 million in additional gross proceeds if all warrants are exercised. Proceeds are intended for clinical development, working capital and general corporate purposes.
Atossa Therapeutics (Nasdaq: ATOS) reported two (Z)-endoxifen abstracts accepted for ASCO 2026. Preclinical data show robust estrogen receptor inhibition across key ESR1 mutations, while the ongoing Phase 2 EVANGELINE trial evaluates 40 mg daily (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal ER+/HER2- breast cancer.
Atossa Therapeutics (NASDAQ: ATOS)/b) announced acceptance of a review manuscript in on (Z)-endoxifen as a potential modulator of utrophin pathways in Duchenne muscular dystrophy (DMD).
The article outlines how (Z)-endoxifen may favor utrophin expression and function and proposes preclinical studies and biomarker development as next steps.